Cargando…
Anti‐tumour necrosis factor‐α‐induced lupus in a patient receiving infliximab for sarcoidosis
Infliximab is a chimeric monoclonal antibody against tumour necrosis factor (TNF)‐α, with a wide variety of uses. Monoclonal antibody therapies specifically targeting TNF‐α, have emerged as a novel treatment option for patients with refractory sarcoidosis, with infliximab being the most widely used....
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280438/ https://www.ncbi.nlm.nih.gov/pubmed/35845717 http://dx.doi.org/10.1002/rcr2.1006 |